PARADIGM Biopharma is currently conducting phase 2 clinical trials in Queensland, looking at a drug called Pentosan Polysulfate Sodium (PPS) as a treatment for Ross River Fever.
Currently there is no treatment for the condition, with pre-clinical research conducted in partnership with Griffith University showing promising results that PPS can halt the progression of the disease, reduce its duration and severity and significantly reduce the risk of ongoing complications caused by cartilage breakdown.
Brisbane's Mater Research is undertaking the phase 2 trial, which has been approved after more than a year of proof of concept studies.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jul 17
